Transforming Care in C3G and IC-MPGN: Advancing Diagnosis, Disease Monitoring & Targeted Complement Therapy Across the Patient Journey
Join our faculty to review best practices for managing pediatric and adult patients with complement-mediated kidney diseases such as C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Strengthen your diagnostic approach and gain practical guidance on the use of recently approved complement inhibitor therapies in these rare diseases.
Supported by an educational grant from Apellis
1-3 of 3
A Case-Based Discussion on Managing Adult Patients With C3G or IC-MPGN in the Era of Complement Inhibition
CME/CEA Case-Based Discussion on Managing Adult Patients With C3G or IC-MPGN in the Era of Complement Inhibition
Kenar D. Jhaveri, MD
Shikha Wadhwani MD, MS
Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
CME/CEEngaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Sayna Norouzi, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD